FDA scientists vs advisers on peptides, the split tells you everything

Posted by grinder265 in Safety & Side Effects - 3 points, 4 comments.

https://www.npr.org/2026/06/30/nx-s1-5876301/peptides-fda-panel-compounding-rfk

NPR has the FDA's own scientists basically pushing back on the panel that wants to loosen restrictions on things like BPC-157 and TB-500. The scientists are saying the safety data just isn't there and the advisers are voting to add them to the compounding list anyway. That split matters to me because the people reviewing the actual studies are saying one thing and the vote is going the other way.

What bugs me is the framing keeps making it sound like this is a MAHA vs FDA fight when really it's a data fight. Either the evidence supports safety or it doesn't, and the scientists inside the agency seem to think it doesn't. Ngl it feels like a few popular compounds are going to get the green light based on hype more than the actual literature.

Curious what people here think, is this a legit path to cleaner access or just opening the door to another wild west situation?

Comments

• leah_vo2max: I think the data point you raised is the right frame, not the political one. The compounding question is genuinely separate from whether these things work or are safe, and conflating them muddies every conversation. To be fair, the compounding list was never meant to be an efficacy stamp, it was a workaround for people who cant access pharmaceutical grade product. Thats not the same as saying the compound is good to go. My worry is exactly yours, that popularity gets mistaken for evidence and s
• grinder265: Yeah the compounding list not being an efficacy stamp is the part I keep coming back to, you nailed that distinction. But ngl thats kinda what scares me more, if its just an access workaround with no safety gate then whats actually stopping anything from getting on there? Like wheres the threshold, does a compound just need enough forum noise and a sympathetic vote The thing that got me about the NPR piece was the scientists werent even saying these are dangerous, they were saying we literally
• tiredmira: Exactly this. Compounding list being a workaround vs an efficacy stamp is the distinction that keeps getting lost in every thread about this stuff. The popularity = evidence thing is what actually scares me. Forums aren't safety data, they're anecdotes. And a panel vote doesn't make anecdotes into RCTs 😅
• grinder265: Yeah that's the part i keep coming back to. Anecdotes aren't RCTs no matter how many people swear by something on a forum, and a popularity contest at the panel level isn't gonna fix that. My worry is the vote ends up framed as "the FDA finally listening to patients" when really it's the advisers overriding their own scientists. If the safety data isn't there yet the answer should be fund the studies not just let it through compounding.

Community discussion - research and educational context only. Not medical advice.